Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Ogbe A. et al, (2022), JCI Insight, 7
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J. et al, (2021), J Immunother Cancer, 9
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Datoo MS. et al, (2021), Lancet, 397, 1809 - 1818
Efficacy of a low dose candidate malaria vaccine, R21 in adjuvant Matrix-M™, with seasonal administration to children in Burkina Faso
EWER K. et al, (2021), The Lancet
Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer
Tuthill M. et al, (2020), ANNALS OF ONCOLOGY, 31, S543 - S543
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM. et al, (2020), Lancet, 396, 467 - 478
Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.
Tuthill M. et al, (2020), JOURNAL OF CLINICAL ONCOLOGY, 38